Works matching IS 21534888 AND DT 2019 AND VI 10 AND IP 2
Results: 21
Strategic Insights on Midsize Employers and Cancer Care Coverage.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 34
- By:
- Publication type:
- Article
SM-88, a Novel Tumor Metabolism--Altering Regimen, Shows Promise as Third-Line Therapy for Metastatic Pancreatic Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 33
- By:
- Publication type:
- Article
Triple-Drug Regimen Improves Survival in Metastatic Colorectal Cancer with BRAF V600E Mutation.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 32
- By:
- Publication type:
- Article
Pembrolizumab a Promising Second-Line Option in PD-L1 Expressing Advanced Esophageal Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 31
- Publication type:
- Article
Adjuvant Therapy with Durvalumab Shows Promise in Advanced Esophageal Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 31
- By:
- Publication type:
- Article
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 30
- By:
- Publication type:
- Article
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 28
- By:
- Publication type:
- Article
Adjuvant Chemotherapy May Be Spared in Localized Breast Cancer If pCR Is Attained with Neoadjuvant Chemotherapy.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 26
- By:
- Publication type:
- Article
Tamoxifen 5 mg Daily as Effective as 20 mg in Early Localized Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 25
- By:
- Publication type:
- Article
Sacituzumab, a Novel Antibody-Drug Conjugate, Shows Activity in Heavily Pretreated Urothelial Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 21
- By:
- Publication type:
- Article
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 21
- By:
- Publication type:
- Article
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 20
- By:
- Publication type:
- Article
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 19
- By:
- Publication type:
- Article
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 18
- By:
- Publication type:
- Article
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 17
- By:
- Publication type:
- Article
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 9
- By:
- Publication type:
- Article
FDA NEWS.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 8
- Publication type:
- Article
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article
Don't Blame Drug Prices on "Big Pharma".
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article